Expression of programmed death 1 is correlated with progression of osteosarcoma

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

Recent advances in osteosarcoma

(2014) Sander M Botter et al.   CURRENT OPINION IN PHARMACOLOGY

The Expression of Programmed Death-1 in Circulating CD4+and CD8+T Cells during Hepatitis B Virus Infection Progression and Its Correlation with Clinical Baseline Characteristics

(2014) Ping Xu et al.   Gut and Liver

Involvement of PAR-4 in Cannabinoid-Dependent Sensitization of Osteosarcoma Cells to TRAIL-Induced Apoptosis

(2014) Antonietta Notaro et al.   International Journal of Biological Sciences

Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

(2014) Christopher A. Barker et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity

(2014) Dallas B. Flies et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival

(2014) Junna Oba et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs

(2014) Basile Siewe et al.   PLoS One

Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF- B and MAPK signaling

(2014) N. H. Philip et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity

(2013) Alan G. Ramsay   BRITISH JOURNAL OF HAEMATOLOGY

Osteosarcoma treatment – Where do we stand? A state of the art review

(2013) Anja Luetke et al.   CANCER TREATMENT REVIEWS

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Cytotoxic T-Lymphocyte Antigen-4 Genetic Variants and Risk of Ewing's Sarcoma

(2013) Dapeng Feng et al.   Genetic Testing and Molecular Biomarkers

Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis

(2013) Shufeng Li et al.   INFLAMMATION

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression

(2013) Bo Wei et al.   TUMOR BIOLOGY

Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma

(2013) R. W. Joseph et al.   Cancer Immunology Research

PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection

(2013) A. W. MacFarlane et al.   Cancer Immunology Research

Cytotoxic T-Lymphocyte Antigen-4 Polymorphisms and Susceptibility to Ewing's Sarcoma

(2012) Shufeng Yang et al.   Genetic Testing and Molecular Biomarkers

Cytotoxic T-lymphocyte Antigen-4 Polymorphisms and Susceptibility to Osteosarcoma

(2011) Yang Liu et al.   DNA AND CELL BIOLOGY

Cytotoxic T-Lymphocyte Antigen-4 +49G/A Polymorphism Is Associated with Increased Risk of Osteosarcoma

(2011) Wen Wang et al.   Genetic Testing and Molecular Biomarkers